BioSpace News Archive

Nestlé Health Science, a globally recognized leader in the field of nutritional science, announced the publication of results from the ATLAS Trial in Cell Reports Medicine.

Gritstone bio, Inc. announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is being held virtually and in-person from May 23-26, 2022.

Profound Medical Corp. announced that multiple clinical presentations and product demonstrations performed at the American Urological Association’s 2022 Annual Meeting, which took place from May 13 – 16 in New Orleans, highlighted the ability of TULSA-PRO® to effectively and safely ablate physician-prescribed prostate tissue in an unrivaled variety of patients with prostate cancer and benign prostatic hyperplasia.

Envista Holdings Corporation announced it has entered into a definitive agreement to acquire Osteogenics Biomedical Inc, Allotech LLC and OBI Biologics, Inc.

CTI Clinical Trial and Consulting Services (CTI), a global research service provider, will relocate and expand its European laboratory.

The protection from cervical cancer can currently only be achieved with the use of Gardasil-9 or Cervarix, two vaccines directed against the L1 proteins of HPV.

Akeso Therapeutics, Inc., an early-stage biotechnology company developing engineered natural killer T (NKT) cells for the treatment of cancer, announced today the appointment of Steven A. Porcelli, MD to its Scientific Advisory Board.

Insmed Incorporated reported data from seven presentations across three of its pillars—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder —at the American Thoracic Society 2022 International Conference.

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at the H.C. Wainwright Global Investment Conference.